Prognostic value of CTI for major adverse cardiovascular events in patients With ST-elevation myocardial infarction after primary percutaneous coronary intervention - Scorecard - MDSpire
Advertisement
Prognostic value of CTI for major adverse cardiovascular events in patients With ST-elevation myocardial infarction after primary percutaneous coronary intervention
Clinical Scorecard: Evaluating the Prognostic Significance of CTI in Predicting Major Adverse Cardiovascular Events Following Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction Patients
At a Glance
Category
Detail
Condition
Key Mechanisms
CTI as a composite biomarker reflecting insulin resistance and systemic inflammation, emphasizing its role in predicting MACE.
Target Population
Care Setting
Key Highlights
highlight_2
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Monitor for major adverse cardiovascular events (MACE) post-PCI, with follow-up assessments at 1 month, 6 months, and 1 year.
Risks
Patient & Prescribing Data
CTI may aid in risk stratification and prognostic evaluation, potentially guiding treatment decisions.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
